This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

ICD-10 G31.01 — Semantic variant primary progressive aphasia Special Copayment Reduction: V800

Semantic variant primary progressive aphasia, svPPA의미변이 원발성 진행성 실어증

Synonyms and related terms: semantic dementia (SD), temporal variant FTD, svPPA

Contents
  1. History
  2. Causes
  3. Genetics
  4. General epidemiology
  5. Pathophysiology
  6. Symptoms
  7. Signs
  8. Screening
  9. Diagnosis
  10. Treatment
  11. Prognosis
  12. Prevention
  13. References

1. History

The original description of semantic variant PPA (svPPA) began in 1975 when Elizabeth Warrington reported cases of dementia with selective impairment of semantic memory. In 1989, John Hodges and Karalyn Patterson systematically described the progressive loss of semantic memory in a group of patients with anterior temporal lobe atrophy and named it 'semantic dementia'. In 1992, Snowden, Goulding, and Neary also independently reported a similar group of cases, and it was included as temporal variant FTD in the Lund-Manchester criteria (1994).

The current classification system was established when the three variants of primary progressive aphasia (nonfluent variant (nfvPPA), semantic variant (svPPA), and logopenic variant (lvPPA)) were formally defined in the 2011 international PPA classification criteria (Gorno-Tempini et al.). It is classified as G31.01 in the Korean ICD-10 system. The underlying pathology of semantic dementia is mostly FTLD-TDP (type C), with TDP-43-immunoreactive inclusions concentrated in the anterior temporal lobe, and FTLD-tau (Pick bodies or other tau pathology) is rarely reported.

2. Causes

The underlying neuropathology of semantic variant PPA (svPPA) is mostly (about 80-90%) FTLD-TDP type C. TDP-43 protein translocates from the nucleus to the cytoplasm and forms ubiquitin-positive, p62-positive, TDP-43-immunoreactive inclusions within neurons, and this type causes particularly concentrated damage in the anterior temporal lobe. In a small remainder, FTLD-tau (Pick disease or MAPT variant-related tau pathology) and Alzheimer pathology (atypical AD) are reported as the underlying etiology.

Most cases are sporadic, and in familial cases GRN variants, MAPT variants, and C9orf72 repeat expansions may be the cause. svPPA tends to have a lower familial proportion than behavioral variant FTD (bvFTD). The role of environmental risk factors is currently unclear, and a history of head trauma has been suggested in some studies.

3. Genetics

Familial causes of svPPA reported include loss-of-function variants of GRN (progranulin, 17q21.32), pathogenic variants of MAPT (17q21.31), and hexanucleotide repeat expansion of C9orf72 (9p21.2). GRN variants are associated with FTLD-TDP type A, but in some cases present with an svPPA phenotype. MAPT variants are rarely associated with tau pathology causing a temporal-predominant atrophy pattern. C9orf72 repeat expansion most commonly presents as bvFTD and FTD-ALS, but rare cases presenting as svPPA are also reported.

The genetic architecture of sporadic svPPA without family history has not yet been sufficiently elucidated in GWAS studies. When a GRN variant is suspected, an FTD gene panel is performed stepwise, including plasma progranulin measurement, repeat-primed PCR for C9orf72 repeat expansion, and MAPT sequencing. Genetic counseling must be provided together with predictive testing to family members when a positive result is confirmed.

4. General epidemiology

svPPA accounts for about 15-25% of the frontotemporal dementia (FTD) spectrum and is one of the three main clinical subtypes of FTD. Age at onset is usually in the 50s-70s, tending to be slightly later than bvFTD. Sex distribution is generally equal, though male predominance has been reported in some cohorts. Worldwide prevalence is estimated at about 2-5 per 100,000 population, but reported cases are increasing with improved diagnostic awareness.

Among underlying pathology types, FTLD-TDP type C is overwhelmingly predominant, suggesting that svPPA has a specific pathobiological basis distinct from bvFTD (TDP type A, B, or C9orf72-associated) and nfvPPA (mainly FTLD-tau). As comorbid conditions, behavioral symptoms (conversion to bvFTD), parkinsonian syndromes, and motor neuron disease are reported in a minority. In Korea it is included in overall FTD statistics, and separate prevalence data are limited.

5. Pathophysiology

The core pathology of svPPA is selective neurodegeneration of the anterior temporal lobe (ATL), and the central lesion is the breakdown of the temporal cortical neural network responsible for semantic memory processing. The anterior temporal lobe functions as a 'semantic hub' that integrates linguistic, visual, and auditory conceptual information, and neuronal loss and synaptic loss caused by FTLD-TDP type C pathology in this region lead to category-independent degradation of semantic memory.

The pathological features of FTLD-TDP type C are TDP-43-immunoreactive long dystrophic neurites concentrated in the anterior temporal lobe and sparse intracytoplasmic inclusions; long neurite pathology is characteristic compared with other TDP types. Loss of the nuclear functions of TDP-43 (RNA splicing, mRNA stabilization, transcriptional regulation) leads to collapse of neuronal homeostasis and cell death. Damage to the semantic network causes progressive loss of multisensory conceptual representations, so that both object recognition and naming through linguistic, visual, and tactile pathways decline.

The lesion begins early in the left (or asymmetrically left-predominant) anterior temporal lobe and, as it progresses, spreads to the right anterior temporal lobe and the frontal lobe. When the lesion spreads to the right anterior temporal lobe, prosopagnosia, loss of semantic memory for people, and behavioral symptoms (bvFTD-like features) are added.

6. Symptoms

The core clinical symptom of svPPA is progressive loss of semantic memory, which affects both linguistic and nonverbal semantic representations. Among language symptoms, anomia is most prominent, and it is characteristic that patients themselves recognize and complain that they cannot think of the names of objects. Reduced ability to define words makes dictionary-style explanations impossible, and high-frequency words are preserved but low-frequency words, technical terms, and proper nouns are lost first. After loss of nouns, the tendency to refer to objects as 'it' or 'that thing' increases.

Surface dyslexia is characteristic, with errors in which irregularly spelled words are misread according to phonological rules (e.g., reading "yacht" as /yakt/). Reduced auditory comprehension and impaired naming of objects and pictures are confirmed, but speech fluency and spoken grammar are relatively preserved early on. As loss of nonverbal semantic representations, impaired object and picture recognition (associative agnosia), prosopagnosia, and impaired sound recognition (auditory agnosia) appear as the disease progresses.

Early on, other cognitive domains (episodic memory, visuospatial function, executive function) are relatively preserved and daily life is maintained. However, as the disease progresses, behavioral symptoms (compulsive behavior, disinhibition, apathy, changes in eating habits) are added, reflecting frontal lobe and right temporal lobe involvement. From the point at which prosopagnosia appears, decline in social function accelerates.

7. Signs

On neurological examination, early svPPA often shows no clear focal neurological deficit. On language testing, spontaneous speech is fluent, but empty speech with a lack of content words and an increased frequency of generic pronouns and demonstratives in place of words are observed. Naming errors are marked on the Boston Naming Test (BNT), and the point that there is no or only slight improvement when semantic cues are given distinguishes it from Alzheimer disease, in which performance improves with phonemic cues.

In error analysis of confrontation naming, semantic errors (a different word from the same category) and circumlocution are more prominent than errors based on visual features (perceptual errors: naming a similar-looking object). Decline in semantic knowledge is confirmed on picture-word matching, category sorting, and semantic association tests (Camel & Cactus Test). As right temporal lobe involvement progresses, impairment appears on face recognition tests (Benton FFFRT) and famous-person recognition tests.

Brain MRI characteristically shows marked atrophy of the left (or bilateral, asymmetric) anterior temporal lobe, and FDG-PET confirms anterior temporal hypometabolism. If CSF and amyloid PET tests are negative for Alzheimer pathology, this supports FTLD pathology.

8. Screening

For language screening in svPPA, naming, word comprehension, and semantic memory tests are essential. The Boston Naming Test (BNT) assesses naming of 60 pictures, and marked impairment is seen in svPPA. The semantic association test (Camel & Cactus Test) is a target-choice semantic relationship judgment task and a sensitive tool reflecting the decline of semantic knowledge in svPPA. The Korean version of the Western Aphasia Battery (WAB) assesses four domains (spontaneous speech, auditory comprehension, repetition, and naming) and quantifies the overall pattern of language function impairment in svPPA.

On word fluency tests, semantic fluency (category fluency such as naming animals or vegetables) is markedly reduced, while letter fluency (generating words beginning with a specific letter) is relatively less reduced, a pattern that contrasts with nfvPPA (in which letter fluency is more reduced). The MMSE/MoCA do not adequately reflect the specificity of language symptoms, so their use alone for screening is inappropriate, and a standardized neuropsychological language test battery (such as the Seoul Neuropsychological Screening Battery) is needed. For imaging screening, brain MRI (anterior temporal atrophy) and FDG-PET (anterior temporal hypometabolism) are used first.

9. Diagnosis

Diagnosis of svPPA is made according to the 2011 international PPA classification criteria (Gorno-Tempini et al.). The core diagnostic criteria require that both of the following essential features be met: ① impaired naming on a word list recall test or confrontation naming test, and ② impaired single-word comprehension. Supportive diagnostic features include ③ impaired object knowledge (for low-frequency or low-typicality items), ④ surface dyslexia or surface dysgraphia, ⑤ spared repetition, and ⑥ spared speech production (fluent and grammatically correct speech).

Imaging-supported criteria include atrophy of the anterior temporal lobe (predominant or bilateral) on brain MRI, anterior temporal hypometabolism on FDG-PET, and anterior temporal hypoperfusion on SPECT. In CSF biomarkers, normal Aβ42 and normal or mildly elevated p-tau support FTLD pathology and are useful for differentiation from Alzheimer disease-based lvPPA. Pathological confirmation is made by identifying FTLD-TDP type C with TDP-43 immunohistochemistry in autopsy or biopsy brain tissue.

For differential diagnosis, it is important to distinguish it from logopenic variant PPA (lvPPA; Alzheimer pathology-based, reduced phonological working memory, impaired sentence repetition), nonfluent variant PPA (nfvPPA; FTLD-tau-based, speech motor impairment or agrammatism), Alzheimer disease (predominant episodic memory decline, temporoparietal hypometabolism), and semantic aphasia (based on an acquired lesion, not progressive).

10. Treatment

There is no approved disease-modifying treatment for svPPA, and treatment centers on symptomatic therapy aimed at maintaining language function and preserving communication ability. Speech-language therapy is the center of treatment, and small studies show that word retrieval training, semantic feature analysis, and picture-word association training help temporarily maintain naming ability. Training effects tend to be specific to trained items, and generalization to untrained items is limited.

As communication aids, augmentative and alternative communication (AAC) systems (picture communication boards, speech generating devices, tablet-based AAC apps) are more effective the earlier they are introduced, before speech ability declines. Making personalized communication aids based on photo and object cards helps maintain everyday communication. In the early stage, when cognitive function is relatively preserved, strategic compensation through diary writing, word book management, and external storage of semantic knowledge (storing semantic cues through photos and notes) is useful.

As for drug treatment, cholinesterase inhibitors show no significant effect in svPPA, and when behavioral symptoms accompany, an SSRI or a low-dose atypical antipsychotic may be needed. Caregiver education, communication strategy training, and linkage to community support are essential.

11. Prognosis

svPPA is a progressive neurodegenerative disease with a poor prognosis. Survival from symptom onset to death is about 6-12 years, tending to be slightly longer than bvFTD. Early on, language decline predominates and daily life is relatively maintained, but from the middle stage onward, loss of nonverbal semantic memory, added behavioral symptoms (conversion to a bvFTD pattern when the right temporal and frontal lobes are involved), global cognitive decline, and motor symptoms progress. In the late stage, global loss of communication, complete dependence for daily function, and dysphagia occur.

The PPA Severity Rating Scale (PPASR), Western Aphasia Battery (WAB), and CDR plus FTLD sum score are used to track functional level. Elevated plasma NfL is associated with rapid progression and is being studied as a prognostic biomarker. Advance decision-making, planning for AAC introduction before communication ability declines, and completion of advance directives on life-sustaining treatment should be initiated proactively at the time of early diagnosis.

12. Prevention

There is no established primary prevention for svPPA. When a GRN variant, MAPT variant, or C9orf72 repeat expansion is identified in a familial case, genetic counseling and predictive testing for family members should be considered, and counseling accompanied by a mental health professional should precede it. For general brain health promotion, management of cardiovascular risk factors, regular exercise, social participation, and participation in lifelong education are recommended. Research is ongoing on whether language-stimulating activities (multilingualism, reading, writing, language learning) contribute to strengthening cognitive reserve, but the effect in svPPA remains unclear.

13. References